Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
M Hallek, O Al‐Sawaf - American journal of hematology, 2021 - Wiley Online Library
Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …
Role of Bruton's tyrosine kinase in B cells and malignancies
S Pal Singh, F Dammeijer, RW Hendriks - Molecular cancer, 2018 - Springer
Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic
signaling that is critical for proliferation and survival of leukemic cells in many B cell …
signaling that is critical for proliferation and survival of leukemic cells in many B cell …
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Summary Background Covalent Bruton's tyrosine kinase (BTK) inhibitors are efficacious in
multiple B-cell malignancies, but patients discontinue these agents due to resistance and …
multiple B-cell malignancies, but patients discontinue these agents due to resistance and …
Detection of early seeding of Richter transformation in chronic lymphocytic leukemia
F Nadeu, R Royo, R Massoni-Badosa… - Nature medicine, 2022 - nature.com
Richter transformation (RT) is a paradigmatic evolution of chronic lymphocytic leukemia
(CLL) into a very aggressive large B cell lymphoma conferring a dismal prognosis. The …
(CLL) into a very aggressive large B cell lymphoma conferring a dismal prognosis. The …
Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome
Richter syndrome (RS) arising from chronic lymphocytic leukemia (CLL) exemplifies an
aggressive malignancy that develops from an indolent neoplasm. To decipher the genetics …
aggressive malignancy that develops from an indolent neoplasm. To decipher the genetics …
Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor–modified T cells after failure of ibrutinib
Purpose We evaluated the safety and feasibility of anti-CD19 chimeric antigen receptor–
modified T (CAR-T) cell therapy in patients with chronic lymphocytic leukemia (CLL) who …
modified T (CAR-T) cell therapy in patients with chronic lymphocytic leukemia (CLL) who …
Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia
AW Roberts, MS Davids, JM Pagel… - … England Journal of …, 2016 - Mass Medical Soc
Background New treatments have improved outcomes for patients with relapsed chronic
lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a …
lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a …
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Duvelisib (also known as IPI-145) is an oral, dual inhibitor of phosphatidylinositol 3-kinase δ
and γ (PI3K-δ, γ) being developed for treatment of hematologic malignancies. PI3K-δ, γ …
and γ (PI3K-δ, γ) being developed for treatment of hematologic malignancies. PI3K-δ, γ …
[HTML][HTML] Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Clinical trials that led to ibrutinib's approval for the treatment of chronic lymphocytic leukemia
showed that its side effects differ from those of traditional chemotherapy. Reasons for …
showed that its side effects differ from those of traditional chemotherapy. Reasons for …
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
S Stilgenbauer, B Eichhorst, J Schetelig… - The lancet …, 2016 - thelancet.com
Background Deletion of chromosome 17p (del [17p]) in patients with chronic lymphocytic
leukaemia confers very poor prognosis when treated with standard chemo-immunotherapy …
leukaemia confers very poor prognosis when treated with standard chemo-immunotherapy …